Get started
Work

164P Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma

Year: 2024
Type: article
Abstract: Roginolisib continuously administered inhibits its target at IC90 in patients (pts). In pts with pretreated uveal melanoma (UM), a median overall survival (OS) of 15.9 months (m) (CI95%:10.7-26.4 m) and median PFS of 5.3 m (CI95% 3.7-5.9) was observed. Biomarker data from the completed Phase I DIONE-01 study may explain the mechanism of action of roginolisib.
DOI: 10.1016/j.iotech.2024.100793
Authors: A.M. Di Giacomo, M. Simonelli, F. Santangelo, G. Amato, E. Simonetti, J. Graham, M. Lahn, G. Di Conza, T. Hammett, P. Kaur, T. Ziyang, T. Lakshmikanth, P. Brodin, M. Occhipinti, C. Carlo-Stella, A. Santoro, P. Spiliopoulou, T.R.J. Evans, M. Maio
Institutions: University of Siena, Network Italiano Per la Bioterapia Dei Tumori, Humanitas University, Beatson West of Scotland Cancer Centre, iOnctura SA (Switzerland), Karolinska Institutet, IRCCS Humanitas Research Hospital, University of Glasgow, Ospedale Santa Maria alle Scotte
Language: English
Subfield: Ophthalmology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405374311
FWCI: 0.68
Cites:
Cited by: 2
Related to: 10